+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Hypoparathyroidism and hypocalcemia can develop after surgery, such as thyroid removal, or may be inherited, and sometimes appear in newborns or during pregnancy. These conditions involve low levels of parathyroid hormone or calcium in the blood, whi...

Search Bar & Filters

Found 26 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are collecting data in women who have been exposed to palopegteriparatide during pregnancy to understand the risks to the mother, fetus, and infant. This observational registry study aims to assess pregnancy outcomes, maternal complications, and any adverse effects on the developing fetus, newborn, and infant up to at least one year of age. The study focuses on women with hypoparathyroidism who have been treated with this medication around conception or during pregnancy. Participants include pregnant women who have taken at least one dose of YORVIPATH palopegteriparatide within 15 days before conception or during pregnancy. The medication is prescribed according to normal clinical practice. The study gathers data from these women without altering their treatment and includes only those who provide informed consent or assent with parental consent as applicable. During the study, researchers will collect information on the number of fetuses, pregnancy outcomes, congenital malformations, adverse events, hospitalizations, growth and development milestones, signs of calcium imbalance, infant developmental issues, mortality, and maternal complications. Data will be tracked up to 21 months after exposure to understand both short- and longer-term effects. Participants will provide medical information through healthcare providers, and ongoing monitoring will support safety assessments throughout this period.

Age: 15Years - 50YearsFEMALE
1 location
P

Actively Recruiting

Researchers are evaluating the safety, tolerability, and effectiveness of EXT608 in adults with hypoparathyroidism, a condition characterized by low parathyroid hormone levels affecting calcium balance. This Phase 2, multicenter, randomized, double-blind, placebo-controlled trial aims to better understand how this modified parathyroid hormone attached to vitamin D may work in this population. The study is sponsored by Extend Biosciences Inc. and focuses on adults aged 18 to 65 years who have had hypoparathyroidism for at least 12 months. Participants will receive either EXT608 or a placebo via subcutaneous injection once a week. The trial includes a multiple ascending dose phase, starting with a 50 microgram dose for 4 weeks, followed by individualized dosing for another 8 weeks. The placebo group will receive fixed doses for 4 weeks, then variable doses for 8 weeks. This dosing schedule allows researchers to assess the medications effects at different dose levels and monitor participants closely. During the 12-week treatment period, participants will be monitored for safety and tolerability through tracking of adverse events and laboratory tests. Researchers will also assess pharmacokinetics, serum calcium levels, and calcium supplementation needs. Participants will be asked to comply with study procedures, including using a smartphone diary to record medication doses and symptoms. The trial includes detailed evaluation of laboratory results and clinical outcomes to better understand the impact of EXT608 for hypoparathyroidism.

Age: 18Years - 65YearsAll GendersPhase 2
1 location
I

Actively Recruiting

Researchers are conducting a Phase 3 clinical trial to evaluate the safety, tolerability, and efficacy of palopegteriparatide in adult participants with hypoparathyroidism. The study focuses on adults already receiving palopegteriparatide doses at or above 30 mcg per day. The trial aims to gather additional evidence on the treatment effects and safety profile of higher doses of this medication in this population. Participants will receive daily subcutaneous injections of palopegteriparatide, with doses individually adjusted using either a novel titration algorithm or a previously evaluated titration method. The treatment period lasts 78 weeks, during which participants will be randomly assigned to one of two groups receiving different dose titration strategies. Throughout the study, participants will undergo laboratory assessments to confirm eligibility and monitor health status, including measurements of serum calcium, vitamin D, magnesium, and kidney function. The primary outcome will be assessed at 26 weeks to evaluate treatment efficacy. Safety and tolerability will be continuously monitored during the 78-week treatment period. The trial is conducted in the United States and involves regular visits for dosing and assessments.

Age: 18Years +All GendersPhase 3
9 locations
O

Actively Recruiting

This observational study focuses on lactating female participants who are receiving therapeutic doses of YORVIPATH palopegteriparatide as part of their usual medical care and who have chosen to breastfeed their infants. The purpose is to assess the potential transfer of palopegteriparatide into breast milk, providing important information about exposure during breastfeeding for females with hypoparathyroidism. Participants in this study are lactating females treated with YORVIPATH according to normal clinical practice. The study observes those who have been on a stable daily dose of YORVIPATH for at least 14 days prior to sample collection. This is an opportunistic study that does not involve changes to their treatment but monitors the presence of the drug in breast milk over a six-day period. During the study, participants provide breast milk samples to evaluate the transfer of palopegteriparatide. The main outcome measured is the amount of the drug present in breast milk over six days. Participants continue their usual care and dosing schedules, and researchers collect data without altering treatment. The total participation duration depends on dosing stability and sample collection timing, with no additional interventions beyond monitoring.

Age: 18Years - 50YearsFEMALE
1 location
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of canvuparatide, a once-weekly injectable treatment, for adults with hypoparathyroidism, a condition characterized by low parathyroid hormone levels. This Phase 3 trial compares canvuparatide with a placebo to determine its impact on patients who have had the condition for at least 12 months. Participants will receive either canvuparatide or a placebo, both given via a single-use drug-device combination that delivers a 1 mL subcutaneous injection once a week. The study includes a randomized, double-blind design with parallel groups and will be followed by an open-label extension phase. Dosages vary from 400 to 1600 micrograms per milliliter of the drug in the delivery device. During the study, participants will have regular visits to monitor their response to treatment, including measurements of calcium levels and parathyroid hormone. The main outcome is the proportion of patients who respond to treatment at 26 weeks. Safety and efficacy will be closely assessed throughout the trial, which is expected to continue until 2029. Participants health will be monitored to ensure proper management of hypoparathyroidism and to track any side effects.

Age: 18Years +All GendersPhase 3
22 locations
D

Actively Recruiting

Researchers are evaluating the effects and safety of once-daily palopegteriparatide injections in adolescents aged 12 to under 18 years who have long-term hypoparathyroidism. The study focuses on participants with clinically diagnosed hypoparathyroidism lasting at least 26 weeks and aims to understand how well this treatment works and its safety profile over a long period. Participants will receive palopegteriparatide by subcutaneous injection once daily for up to 234 weeks. During this time, researchers will monitor various health aspects including serum biochemistries, bone mineral density, renal calcifications, hospital visits, adverse events, and patient-reported symptom and impact scores. This is a single-group Phase 3 trial conducted in Europe. Participants will be involved in regular assessments throughout the study, including blood and urine tests, imaging for kidney calcifications, bone health evaluations, and symptom questionnaires. The main outcome is the percentage of participants achieving a specific efficacy endpoint at 26 weeks, with ongoing monitoring continuing through the full 234 weeks. Safety and treatment effects will be closely observed during the entire study period.

Age: 12Years - 18YearsAll GendersPhase 3
3 locations
R

Actively Recruiting

Post-operative hypoparathyroidism PH is a challenging complication following total thyroidectomy, caused by accidental removal or damage to the parathyroid glands. Researchers are evaluating whether the PTeye device, which uses near-infrared autofluorescence NIRAF technology, can help reduce PH by better identifying these glands during surgery. This prospective, single-blinded, randomized controlled trial enrolls patients undergoing total thyroidectomy at a tertiary endocrine surgery unit in Hong Kong. Participants will be randomly assigned to one of two groups one receiving conventional total thyroidectomy and the other undergoing surgery assisted by the PTeye parathyroid detection system. PTeye uses a probe that emits laser and detects near-infrared signals in real time to identify parathyroid glands early during the operation, aiming to avoid their inadvertent removal or devascularization. During the study, participants will receive medical care as usual. Researchers will measure the rate of significant post-operative hypoparathyroidism six months after surgery, along with secondary outcomes such as rates of unintended parathyroid removal, parathyroid auto-transplantation, and parathyroid hormone levels on the day of surgery, the following day, and at three and six months post-operation. The trial starts in September 2025 and continues until December 2028.

Age: 18Years +All GendersPhase Not Applicable
1 location
P

Actively Recruiting

Researchers are evaluating the efficacy, safety, and tolerability of orally administered encaleret tablets in people with chronic hypoparathyroidism, a condition characterized by low parathyroid hormone levels. This Phase 3, multicenter, randomized, double-blind study compares encaleret to a placebo in participants aged 16 years and older. The study aims to understand how well encaleret controls key biochemical markers related to calcium regulation in this condition. Participants will be randomly assigned to receive either encaleret or a placebo during a 24-week double-blind treatment period. After this phase, participants have the option to continue taking encaleret in an open-label long-term extension for up to 192 weeks. Both encaleret and placebo are given as oral tablets, and the study maintains a parallel-group design. During the study, participants will undergo assessments to monitor albumin-corrected blood calcium and 24-hour urine calcium levels, as well as evaluations of calcium and vitamin D supplement use and symptoms of hypoparathyroidism. Safety and tolerability are closely monitored throughout. The primary outcome is measured at 24 weeks, but participants may continue treatment in the extension phase for long-term observation lasting several years.

Age: 16Years +All GendersPhase 3
5 locations
R

Actively Recruiting

Researchers are establishing a registry to include all patients diagnosed with parathyroid diseases such as hyperparathyroidism or hypoparathyroidism who have been evaluated at the Endocrinology Operating Unit. The goal is to collect and study biochemical, clinical, radiological, medico-nuclear, and histological data over a long period to better understand these conditions. This observational study spans 30 years, enrolling patients seen from January 1, 2000, to December 31, 2029. The registry will track patients through at least two endocrinology visits to confirm diagnosis and consent. Data collection includes biochemical tests, clinical symptom monitoring, imaging studies, and histopathological evaluations. Follow-up for each patient is expected to last about 10 years, with continuous updates until the registry closes at the end of 2039. Participants will be observed over time with regular assessments of biochemical markers, clinical symptoms, imaging results, and tissue characteristics related to parathyroid disorders. The research team will monitor these outcomes longitudinally to observe disease progression and related health effects. This study involves no treatment interventions, focusing on collecting comprehensive data to support future research efforts.

Age: 18Years +All Genders
1 location
R

Actively Recruiting

Chronic hypoparathyroidism is a rare condition where the parathyroid glands do not produce enough parathyroid hormone PTH, leading to low calcium and high phosphate levels in the blood. Most cases occur after neck surgeries such as thyroid or parathyroid operations. Current treatments mainly involve calcium and vitamin D supplements, which help control calcium levels but do not fully replace PTHs functions. This registry study aims to better understand the symptoms, long-term health issues, treatments, and overall health of patients with chronic hypoparathyroidism and pseudohypoparathyroidism. The study collects medical data and follows patients over time to document their disease course and treatment outcomes. It also includes a control group of patients who have had thyroid removal but do not have hypoparathyroidism to compare outcomes related to thyroid surgery. The registry gathers detailed information on symptoms, diagnostic methods, biochemical monitoring, organ effects, treatment effectiveness, and quality of life. It also focuses on long-term complications and special events like pregnancies. Participants provide medical information through structured documentation and follow-up visits. The study monitors disease progression, treatment needs, and long-term outcomes over many years. Researchers assess long-term comorbidities related to hypoparathyroidism over a 15-year period. This observational study does not involve experimental treatments but provides valuable data to improve understanding and management of chronic hypoparathyroidism.

Age: 18Years +All Genders
1 location

1-10 of 26

1

Frequently Asked Questions